MK-3655

Merck bags global rights to NGM NASH drug, plans phase 2b trial
Fierce Biotech
Thu, 01/3/19 - 09:45 am
Merck
NASH
NGM Biopharmaceuticals
type 2 diabetes
clinical trials
MK-3655